The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adeno-Associated Virus (AAV) Particles Market Research Report 2025
Synopsis
Adeno-Associated Virus (AAV) particles are small, non-enveloped viruses that belong to the Parvoviridae family. AAV is commonly used in gene therapy and biotechnology as a vector for delivering genetic material into cells. AAV particles are characterized by their ability to infect a broad range of dividing and non-dividing cells, and they are considered relatively safe for therapeutic applications due to their low pathogenicity in humans. In gene therapy, AAV vectors are designed to carry therapeutic genes into target cells, allowing for the correction or replacement of defective genes. AAV particles have shown promise in various medical applications, and ongoing research aims to optimize their efficiency, specificity, and safety for use in treating genetic disorders and other diseases.
The global Adeno-Associated Virus (AAV) Particles market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The cell and gene therapy market is experiencing significant growth driven by ongoing advancements in medical research and biotechnology. Key trends include an increasing number of clinical trials and approvals for cell and gene therapies, indicating a growing acceptance of these innovative treatments. There is a notable emphasis on personalized medicine, with therapies tailored to individual patients based on genetic factors. Collaborations and partnerships between pharmaceutical companies and research institutions are on the rise, fostering innovation and the development of novel therapies. Manufacturing scalability and process optimization are focal points to meet the rising demand for these therapies. Additionally, efforts to address regulatory and reimbursement challenges are ongoing, reflecting the dynamic nature of the cell and gene therapy landscape. Overall, the market is evolving rapidly, with a focus on expanding therapeutic applications and improving accessibility for patients globally.
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Particles.
Report Scope
The Adeno-Associated Virus (AAV) Particles market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adeno-Associated Virus (AAV) Particles market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno-Associated Virus (AAV) Particles manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
Addgene
Takara
Charles River Laboratories
SIRION Biotech
Thermo Fisher Scientific
OriGene Technologies
Cell Biolabs
GenScript
VectorBuilder
GeneCopoeia
AMSBIO
Creative Biogene
BPS Bioscience
Oxford Biomedica
FUJIFILM Diosynth Biotechnologies
Aldevron
Segment by Type
Custom-made
Pre-made
Segment by Application
Medical Institutions
Research Institute
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adeno-Associated Virus (AAV) Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adeno-Associated Virus (AAV) Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Adeno-Associated Virus (AAV) particles are small, non-enveloped viruses that belong to the Parvoviridae family. AAV is commonly used in gene therapy and biotechnology as a vector for delivering genetic material into cells. AAV particles are characterized by their ability to infect a broad range of dividing and non-dividing cells, and they are considered relatively safe for therapeutic applications due to their low pathogenicity in humans. In gene therapy, AAV vectors are designed to carry therapeutic genes into target cells, allowing for the correction or replacement of defective genes. AAV particles have shown promise in various medical applications, and ongoing research aims to optimize their efficiency, specificity, and safety for use in treating genetic disorders and other diseases.
The global Adeno-Associated Virus (AAV) Particles market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The cell and gene therapy market is experiencing significant growth driven by ongoing advancements in medical research and biotechnology. Key trends include an increasing number of clinical trials and approvals for cell and gene therapies, indicating a growing acceptance of these innovative treatments. There is a notable emphasis on personalized medicine, with therapies tailored to individual patients based on genetic factors. Collaborations and partnerships between pharmaceutical companies and research institutions are on the rise, fostering innovation and the development of novel therapies. Manufacturing scalability and process optimization are focal points to meet the rising demand for these therapies. Additionally, efforts to address regulatory and reimbursement challenges are ongoing, reflecting the dynamic nature of the cell and gene therapy landscape. Overall, the market is evolving rapidly, with a focus on expanding therapeutic applications and improving accessibility for patients globally.
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Particles, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Particles.
Report Scope
The Adeno-Associated Virus (AAV) Particles market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adeno-Associated Virus (AAV) Particles market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno-Associated Virus (AAV) Particles manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
Addgene
Takara
Charles River Laboratories
SIRION Biotech
Thermo Fisher Scientific
OriGene Technologies
Cell Biolabs
GenScript
VectorBuilder
GeneCopoeia
AMSBIO
Creative Biogene
BPS Bioscience
Oxford Biomedica
FUJIFILM Diosynth Biotechnologies
Aldevron
Segment by Type
Custom-made
Pre-made
Segment by Application
Medical Institutions
Research Institute
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adeno-Associated Virus (AAV) Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adeno-Associated Virus (AAV) Particles in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Adeno-Associated Virus (AAV) Particles Market Overview
1.1 Product Overview and Scope of Adeno-Associated Virus (AAV) Particles
1.2 Adeno-Associated Virus (AAV) Particles Segment by Type
1.2.1 Global Adeno-Associated Virus (AAV) Particles Market Value Comparison by Type (2024-2030)
1.2.2 Custom-made
1.2.3 Pre-made
1.3 Adeno-Associated Virus (AAV) Particles Segment by Application
1.3.1 Global Adeno-Associated Virus (AAV) Particles Market Value by Application: (2024-2030)
1.3.2 Medical Institutions
1.3.3 Research Institute
1.4 Global Adeno-Associated Virus (AAV) Particles Market Size Estimates and Forecasts
1.4.1 Global Adeno-Associated Virus (AAV) Particles Revenue 2019-2030
1.4.2 Global Adeno-Associated Virus (AAV) Particles Sales 2019-2030
1.4.3 Global Adeno-Associated Virus (AAV) Particles Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Adeno-Associated Virus (AAV) Particles Market Competition by Manufacturers
2.1 Global Adeno-Associated Virus (AAV) Particles Sales Market Share by Manufacturers (2019-2024)
2.2 Global Adeno-Associated Virus (AAV) Particles Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Adeno-Associated Virus (AAV) Particles Average Price by Manufacturers (2019-2024)
2.4 Global Adeno-Associated Virus (AAV) Particles Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adeno-Associated Virus (AAV) Particles, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adeno-Associated Virus (AAV) Particles, Product Type & Application
2.7 Adeno-Associated Virus (AAV) Particles Market Competitive Situation and Trends
2.7.1 Adeno-Associated Virus (AAV) Particles Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adeno-Associated Virus (AAV) Particles Players Market Share by Revenue
2.7.3 Global Adeno-Associated Virus (AAV) Particles Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adeno-Associated Virus (AAV) Particles Retrospective Market Scenario by Region
3.1 Global Adeno-Associated Virus (AAV) Particles Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Adeno-Associated Virus (AAV) Particles Global Adeno-Associated Virus (AAV) Particles Sales by Region: 2019-2030
3.2.1 Global Adeno-Associated Virus (AAV) Particles Sales by Region: 2019-2024
3.2.2 Global Adeno-Associated Virus (AAV) Particles Sales by Region: 2025-2030
3.3 Global Adeno-Associated Virus (AAV) Particles Global Adeno-Associated Virus (AAV) Particles Revenue by Region: 2019-2030
3.3.1 Global Adeno-Associated Virus (AAV) Particles Revenue by Region: 2019-2024
3.3.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Region: 2025-2030
3.4 North America Adeno-Associated Virus (AAV) Particles Market Facts & Figures by Country
3.4.1 North America Adeno-Associated Virus (AAV) Particles Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Adeno-Associated Virus (AAV) Particles Sales by Country (2019-2030)
3.4.3 North America Adeno-Associated Virus (AAV) Particles Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adeno-Associated Virus (AAV) Particles Market Facts & Figures by Country
3.5.1 Europe Adeno-Associated Virus (AAV) Particles Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Adeno-Associated Virus (AAV) Particles Sales by Country (2019-2030)
3.5.3 Europe Adeno-Associated Virus (AAV) Particles Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Adeno-Associated Virus (AAV) Particles Market Facts & Figures by Country
3.6.1 Asia Pacific Adeno-Associated Virus (AAV) Particles Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Adeno-Associated Virus (AAV) Particles Sales by Country (2019-2030)
3.6.3 Asia Pacific Adeno-Associated Virus (AAV) Particles Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Adeno-Associated Virus (AAV) Particles Market Facts & Figures by Country
3.7.1 Latin America Adeno-Associated Virus (AAV) Particles Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Adeno-Associated Virus (AAV) Particles Sales by Country (2019-2030)
3.7.3 Latin America Adeno-Associated Virus (AAV) Particles Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Adeno-Associated Virus (AAV) Particles Market Facts & Figures by Country
3.8.1 Middle East and Africa Adeno-Associated Virus (AAV) Particles Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Adeno-Associated Virus (AAV) Particles Sales by Country (2019-2030)
3.8.3 Middle East and Africa Adeno-Associated Virus (AAV) Particles Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adeno-Associated Virus (AAV) Particles Sales by Type (2019-2030)
4.1.1 Global Adeno-Associated Virus (AAV) Particles Sales by Type (2019-2024)
4.1.2 Global Adeno-Associated Virus (AAV) Particles Sales by Type (2025-2030)
4.1.3 Global Adeno-Associated Virus (AAV) Particles Sales Market Share by Type (2019-2030)
4.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Type (2019-2030)
4.2.1 Global Adeno-Associated Virus (AAV) Particles Revenue by Type (2019-2024)
4.2.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Type (2025-2030)
4.2.3 Global Adeno-Associated Virus (AAV) Particles Revenue Market Share by Type (2019-2030)
4.3 Global Adeno-Associated Virus (AAV) Particles Price by Type (2019-2030)
5 Segment by Application
5.1 Global Adeno-Associated Virus (AAV) Particles Sales by Application (2019-2030)
5.1.1 Global Adeno-Associated Virus (AAV) Particles Sales by Application (2019-2024)
5.1.2 Global Adeno-Associated Virus (AAV) Particles Sales by Application (2025-2030)
5.1.3 Global Adeno-Associated Virus (AAV) Particles Sales Market Share by Application (2019-2030)
5.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Application (2019-2030)
5.2.1 Global Adeno-Associated Virus (AAV) Particles Revenue by Application (2019-2024)
5.2.2 Global Adeno-Associated Virus (AAV) Particles Revenue by Application (2025-2030)
5.2.3 Global Adeno-Associated Virus (AAV) Particles Revenue Market Share by Application (2019-2030)
5.3 Global Adeno-Associated Virus (AAV) Particles Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Lonza
6.1.1 Lonza Corporation Information
6.1.2 Lonza Description and Business Overview
6.1.3 Lonza Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Lonza Adeno-Associated Virus (AAV) Particles Product Portfolio
6.1.5 Lonza Recent Developments/Updates
6.2 Addgene
6.2.1 Addgene Corporation Information
6.2.2 Addgene Description and Business Overview
6.2.3 Addgene Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Addgene Adeno-Associated Virus (AAV) Particles Product Portfolio
6.2.5 Addgene Recent Developments/Updates
6.3 Takara
6.3.1 Takara Corporation Information
6.3.2 Takara Description and Business Overview
6.3.3 Takara Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takara Adeno-Associated Virus (AAV) Particles Product Portfolio
6.3.5 Takara Recent Developments/Updates
6.4 Charles River Laboratories
6.4.1 Charles River Laboratories Corporation Information
6.4.2 Charles River Laboratories Description and Business Overview
6.4.3 Charles River Laboratories Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Charles River Laboratories Adeno-Associated Virus (AAV) Particles Product Portfolio
6.4.5 Charles River Laboratories Recent Developments/Updates
6.5 SIRION Biotech
6.5.1 SIRION Biotech Corporation Information
6.5.2 SIRION Biotech Description and Business Overview
6.5.3 SIRION Biotech Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.5.4 SIRION Biotech Adeno-Associated Virus (AAV) Particles Product Portfolio
6.5.5 SIRION Biotech Recent Developments/Updates
6.6 Thermo Fisher Scientific
6.6.1 Thermo Fisher Scientific Corporation Information
6.6.2 Thermo Fisher Scientific Description and Business Overview
6.6.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Particles Product Portfolio
6.6.5 Thermo Fisher Scientific Recent Developments/Updates
6.7 OriGene Technologies
6.6.1 OriGene Technologies Corporation Information
6.6.2 OriGene Technologies Description and Business Overview
6.6.3 OriGene Technologies Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.4.4 OriGene Technologies Adeno-Associated Virus (AAV) Particles Product Portfolio
6.7.5 OriGene Technologies Recent Developments/Updates
6.8 Cell Biolabs
6.8.1 Cell Biolabs Corporation Information
6.8.2 Cell Biolabs Description and Business Overview
6.8.3 Cell Biolabs Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Cell Biolabs Adeno-Associated Virus (AAV) Particles Product Portfolio
6.8.5 Cell Biolabs Recent Developments/Updates
6.9 GenScript
6.9.1 GenScript Corporation Information
6.9.2 GenScript Description and Business Overview
6.9.3 GenScript Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.9.4 GenScript Adeno-Associated Virus (AAV) Particles Product Portfolio
6.9.5 GenScript Recent Developments/Updates
6.10 VectorBuilder
6.10.1 VectorBuilder Corporation Information
6.10.2 VectorBuilder Description and Business Overview
6.10.3 VectorBuilder Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.10.4 VectorBuilder Adeno-Associated Virus (AAV) Particles Product Portfolio
6.10.5 VectorBuilder Recent Developments/Updates
6.11 GeneCopoeia
6.11.1 GeneCopoeia Corporation Information
6.11.2 GeneCopoeia Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.11.3 GeneCopoeia Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.11.4 GeneCopoeia Adeno-Associated Virus (AAV) Particles Product Portfolio
6.11.5 GeneCopoeia Recent Developments/Updates
6.12 AMSBIO
6.12.1 AMSBIO Corporation Information
6.12.2 AMSBIO Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.12.3 AMSBIO Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.12.4 AMSBIO Adeno-Associated Virus (AAV) Particles Product Portfolio
6.12.5 AMSBIO Recent Developments/Updates
6.13 Creative Biogene
6.13.1 Creative Biogene Corporation Information
6.13.2 Creative Biogene Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.13.3 Creative Biogene Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Creative Biogene Adeno-Associated Virus (AAV) Particles Product Portfolio
6.13.5 Creative Biogene Recent Developments/Updates
6.14 BPS Bioscience
6.14.1 BPS Bioscience Corporation Information
6.14.2 BPS Bioscience Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.14.3 BPS Bioscience Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.14.4 BPS Bioscience Adeno-Associated Virus (AAV) Particles Product Portfolio
6.14.5 BPS Bioscience Recent Developments/Updates
6.15 Oxford Biomedica
6.15.1 Oxford Biomedica Corporation Information
6.15.2 Oxford Biomedica Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.15.3 Oxford Biomedica Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Oxford Biomedica Adeno-Associated Virus (AAV) Particles Product Portfolio
6.15.5 Oxford Biomedica Recent Developments/Updates
6.16 FUJIFILM Diosynth Biotechnologies
6.16.1 FUJIFILM Diosynth Biotechnologies Corporation Information
6.16.2 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.16.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.16.4 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Particles Product Portfolio
6.16.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
6.17 Aldevron
6.17.1 Aldevron Corporation Information
6.17.2 Aldevron Adeno-Associated Virus (AAV) Particles Description and Business Overview
6.17.3 Aldevron Adeno-Associated Virus (AAV) Particles Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Aldevron Adeno-Associated Virus (AAV) Particles Product Portfolio
6.17.5 Aldevron Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adeno-Associated Virus (AAV) Particles Industry Chain Analysis
7.2 Adeno-Associated Virus (AAV) Particles Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adeno-Associated Virus (AAV) Particles Production Mode & Process
7.4 Adeno-Associated Virus (AAV) Particles Sales and Marketing
7.4.1 Adeno-Associated Virus (AAV) Particles Sales Channels
7.4.2 Adeno-Associated Virus (AAV) Particles Distributors
7.5 Adeno-Associated Virus (AAV) Particles Customers
8 Adeno-Associated Virus (AAV) Particles Market Dynamics
8.1 Adeno-Associated Virus (AAV) Particles Industry Trends
8.2 Adeno-Associated Virus (AAV) Particles Market Drivers
8.3 Adeno-Associated Virus (AAV) Particles Market Challenges
8.4 Adeno-Associated Virus (AAV) Particles Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
